Tricuspid-Valve Intervention in Heart Failure — Randomized Controlled Trial Overview

Title and publication details

The PubMed record is for a randomized controlled trial titled Tricuspid-Valve Intervention in Heart Failure, published in the New England Journal of Medicine (NEJM). Bibliographic details in the record list the publication date as 2026 Oct 8 in volume 395, issue 14, pages 1363–1373, with an electronic preprint (Epub) date of 2026 Aug 30. The DOI provided is 10.1056/NEJMoa2606934. A full-text link to NEJM/Atypon is supplied in the PubMed entry.

Authorship and investigator groups

The article lists a large multicenter author group with lead authors Jörg Hausleiter and Thomas J. Stocker and numerous coauthors representing university hospitals and heart centers across Germany. Affiliations include Ludwig-Maximilians-Universität München, the German Center for Cardiovascular Research (DZHK) partner sites, Technical University of Munich Deutsches Herzzentrum, and multiple university medical centers (for example, Mainz, Tübingen, Ulm, Hamburg, Kiel, Leipzig, Freiburg, Essen, Cologne, Bonn, and Frankfurt). Additional collaborator affiliations include institutions in Dublin, Ireland.

The corporate author is the TRIC-I-HF-DZHK24 Investigators, indicating a coordinated investigational group across multiple centers. The PubMed page displays extensive collaborator and affiliation information but does not include trial-specific personnel roles beyond the author and collaborator listings.

Study classification and trial registry indicators

PubMed classifies the article as a Randomized Controlled Trial. The record includes the NEJM citation and DOI, supporting that this is a peer-reviewed randomized intervention study published in a major clinical journal. The PubMed excerpt does not display a trial registration number or registry name within the provided text; if present, that information was not included in the supplied content.

Available links to full text and DOI

The PubMed entry includes a direct link to the NEJM full-text options (Atypon) associated with DOI 10.1056/NEJMoa2606934. Readers seeking complete trial methodology, statistical analyses, primary and secondary outcomes, safety data, and authors’ interpretation should consult the NEJM full text via the DOI link. PubMed also provides navigation entries for Title & authors, Abstract, Similar articles, Cited by, and Related information, which may include supplemental data when accessed in full.

Information not reported in the PubMed excerpt and limitations

The provided PubMed content excerpt is limited to bibliographic metadata, authorship, affiliations, and site navigation elements. The following items were not reported in the supplied source text and therefore cannot be summarized or interpreted here:

• Patient population characteristics (sample size, inclusion and exclusion criteria, baseline demographics, heart-failure phenotype or staging).
• Specific nature of the tricuspid-valve intervention (device or repair technique, procedural approach, operator experience, concomitant therapies).
• Trial design details (randomization process, control or comparator arm characteristics, blinding, duration of follow-up, primary and secondary endpoints).
• Numerical results including efficacy outcomes, safety events, statistical significance, effect sizes, confidence intervals, and subgroup analyses.
• Adverse-event profiles, procedural complications, and periprocedural management strategies.
• Authors’ conclusions, clinical recommendations, limitations, and suggested avenues for practice change.

Because these core trial elements are absent from the excerpt, this summary refrains from inferring any outcomes, effect sizes, or clinical recommendations that were not explicitly provided in the source.

Implications for clinicians and next steps

From the PubMed metadata alone, this work represents a randomized controlled trial of tricuspid-valve intervention in patients with heart failure reported in NEJM by a large multicenter investigator group. Such a study is likely to be relevant to clinical cardiologists, heart-failure specialists, interventional cardiologists, and multidisciplinary teams managing tricuspid regurgitation in the context of heart failure.

However, because procedural details, patient selection, endpoints, and results were not available in the provided PubMed excerpt, clinicians should access the NEJM full text (doi: 10.1056/NEJMoa2606934) or the PubMed abstract and supplemental materials to evaluate:

• Whether the intervention demonstrates clinically meaningful benefit on symptoms, functional status, hospitalization rates, or mortality.
• Safety and complication rates, including device- or procedure-specific risks.
• Applicability to patient subgroups (for example, secondary vs primary tricuspid regurgitation, right- vs left-sided heart-failure phenotypes, degree of right ventricular dysfunction).
• Practical considerations for implementation, operator training, and center experience.

Until the full methods and results are reviewed, no changes to clinical practice should be recommended solely on the basis of the bibliographic record provided here.

References and access

The PubMed entry cites NEJM with DOI 10.1056/NEJMoa2606934 and provides a link to NEJM/Atypon for full-text options. For a complete, reliable appraisal, consult the NEJM article and any linked supplements or trial registration entries. The PubMed record also lists the corporate investigative group TRIC-I-HF-DZHK24 Investigators for reference.

Note on source limitations

All statements above are restricted to information available in the provided PubMed excerpt. Specific trial design elements, numerical findings, and authors’ interpretations were not included in the source content and therefore were not reported here.